Lixte Biotechnology Holdings, Inc.
NCM: LIXTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Lixte Biotechnology Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LIXT Z-Score →About Lixte Biotechnology Holdings, Inc.
Healthcare
Biotechnology
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
📊 Fundamental Analysis
Lixte Biotechnology Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -102.0%, which indicates that capital utilization is currently under pressure.
At a current price of $3.05, LIXT currently sits at the 43rd percentile of its 52-week range (Range: $0.64 - $6.26).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$35.43M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.95
52W High
$6.26
52W Low
$0.64
Avg Volume
62K
Day High
Day Low